User menu

Prevalence of drug hydroxylator phenotypes in Belgium.

Bibliographic reference Leclercq, V. ; Desager, Jean-Pierre ; van Nieuwenhuyze, Y ; Harvengt, C.. Prevalence of drug hydroxylator phenotypes in Belgium.. In: European journal of clinical pharmacology, Vol. 33, no. 4, p. 439-40 (1987)
Permanent URL http://hdl.handle.net/2078.1/11802
  1. Alvan G, Von Bahr C, Seideman P, Sjoqvist F (1982) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 2: 333
  2. Dayer P, Balant L, Courvoisier F, Kupfer A, Kubli A, Gorgia A, Fabre J (1982) The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 7: 73?77
  3. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183?187
  4. Eichelbaum M, Baur M, Osikowska B, Tieves B, Zekorn C, Rittner Ch (1986) The gene controlling polymorphic sparteine oxidation is located on chromosome 22 in close linkage to P1 blood group. Acta Pharmacol Toxicol 59 [S5, Abst I]: 44
  5. Evans DAP, Mahgoub A, Sloan TB, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102?105
  6. Jacqz E, Hall SD, Branch RA (1986) Genetically determined polymorphisms in drug oxidation. Hepatology 6: 1020?1032
  7. Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 133: 161?166